Renzenbrink & Partner has advised Bruker Corporation on the acquisition of JPK Instruments AG, a leading manufacturer of nanoanalytical instruments based in Berlin. JPK’s products enable biomolecular and cellular imaging as well as force measurements on individual molecules, cells and body tissue. <\/p>\n\n
With sales of nearly $2 billion and more than 6,000 employees worldwide, NASDAQ-listed Bruker Corporation is a global manufacturer of high-end analytical instruments used in science & research, pharmaceutical\/biotechnology, clinical diagnostics and industry. The company operates in the Life Science Tools & Diagnostics sector and has built a reputation for innovation and quality. JPK’s products and expertise in life science applications will allow Bruker to leverage synergies with its existing portfolio of advanced fluorescence microscopy products
Renzenbrink & Partner advised Bruker Corporation comprehensively on all legal aspects of the transaction.<\/p>\n\n
The Renzenbrink & Partner team consisted of partners Dr. Andreas Stoll<\/a> (M&A\/Corporate), Marc H. Kotyrba<\/a> (Tax) and Dr. Gunnar Schm\u00fcser (Finance) as well as associates Dr. Alexander Haunschild<\/a>, Dr. Niels Maier<\/a> and Dr. Florian Seitz.<\/p>\n\n For employment law aspects, Renzenbrink & Partner worked together with Dr. Holger Meyer and Sophie Kuske from the law firm Schramm Meyer Kuhnke. Dr. Kai-Uwe Plath and Dr. Jan-Michael Grages from the law firm KNPZ assisted in the area of IP law. Dr. Andreas Hahn from the law firm Oppenl\u00e4nder advised on competition law aspects. <\/p>\n","protected":false},"featured_media":2068,"template":"","class_list":["post-1494","deals","type-deals","status-publish","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"\n